HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial.

Abstract
Seventy-two patients older than 60 years of age who received a diagnosis of herpes zoster (HZ) were entered into a randomized, double-blind, placebo-controlled trial of daily amitriptyline 25 mg. Treatment with either amitriptyline or placebo continued for 90 days after diagnosis. Pain prevalence at 6 months was the primary outcome. Results showed that early treatment with low-dose amitriptyline reduced pain prevalence by more than one-half (p < 0.05; odds ratio, 2.9:1) This finding makes a strong case for the pre-emptive administration of amitriptyline, in combination with an antiviral drug, to elderly patients with acute herpes zoster.
AuthorsD Bowsher
JournalJournal of pain and symptom management (J Pain Symptom Manage) Vol. 13 Issue 6 Pg. 327-31 (Jun 1997) ISSN: 0885-3924 [Print] UNITED STATES
PMID9204652 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic Uptake Inhibitors
  • Amitriptyline
Topics
  • Adrenergic Uptake Inhibitors (administration & dosage, therapeutic use)
  • Aged
  • Aged, 80 and over
  • Amitriptyline (administration & dosage, therapeutic use)
  • Chi-Square Distribution
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Herpes Zoster (complications, drug therapy)
  • Humans
  • Male
  • Middle Aged
  • Neuralgia (drug therapy, epidemiology, etiology)
  • Odds Ratio
  • Pain Measurement (drug effects)
  • Prevalence
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: